Beyond IC50-A computational dynamic model of drug resistance in enzyme inhibition treatment.

ABSTRACT: Resistance to therapy is a major clinical obstacle to treatment of cancer and communicable diseases. Drug selection in treatment of patients where the disease is showing resistance to therapy is often guided by IC50 or fold-IC50 values. In this work, through a model of the treatment of chronic myeloid leukaemia (CML), we contest using fold-IC50 values as a guide for treatment selection. CML is a blood cancer that is treated with Abl1 inhibitors, and is often seen as a model for targeted therapy and drug resistance. Resistance to the first-line treatment occurs in approximately one in four patients. The most common cause of resistance is mutations in the Abl1 enzyme. Different mutant Abl1 enzymes show resistance to different Abl1 inhibitors and the mechanisms that lead to resistance for var

SUBMITTER: Roadnight Sheehan J 

PROVIDER: S-EPMC11575782 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature